146426-40-6 Usage
Uses
Used in Anticancer Applications:
Flavopiridol is used as an antineoplastic agent for its ability to inhibit cyclin-dependent kinases, which play a crucial role in regulating cell cycle progression. By targeting CDKs, flavopiridol can effectively arrest the cell cycle, leading to the inhibition of cancer cell growth and proliferation. It is particularly effective against various types of cancer, including solid tumors.
Used in Pharmaceutical Industry:
Flavopiridol is used as a potent inhibitor of CDK9, making it a valuable postexposure drug target for adenoviruses. This application has significant implications in the development of antiviral therapies and the treatment of adenovirus-related diseases.
Anticancer Research
It is a synthetic derivative of rohitukine plant alkaloid which is obtained fromDysoxylum binectariferum, which is active against leukemia, lymphomas and solidtumors (Shoeb 2006).
Check Digit Verification of cas no
The CAS Registry Mumber 146426-40-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,6,4,2 and 6 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 146426-40:
(8*1)+(7*4)+(6*6)+(5*4)+(4*2)+(3*6)+(2*4)+(1*0)=126
126 % 10 = 6
So 146426-40-6 is a valid CAS Registry Number.
InChI:InChI=1/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24,26-27H,6-7,10H2,1H3/t12-,17+/m1/s1
146426-40-6Relevant academic research and scientific papers
COMBINATION THERAPIES FOR TREATMENT OF MYELODYSPLASTIC SYNDROME
-
Paragraph 00626-00627; 00631, (2021/06/11)
The present invention relates to methods for treatment of myelodysplastic syndrome (MDS) by administration of a hypomethylating agent (HMA), such as azacitidine or decitabine, or a prodrug of either of the foregoing, or a pharmaceutically acceptable salt of any of the foregoing, and alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing.
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER
-
Paragraph 00346; 00369; 00370, (2020/07/05)
A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
METHODS FOR TREATING CASTRATION-RESISTANT AND CASTRATION- SENSITIVE PROSTATE CANCER
-
Page/Page column 86-87, (2020/07/05)
Methods of treating castration-resistant and castrati on- sensitive prostate cancer using a compound having the following structure (I): or a pharmaceutically acceptable salt or zwitterionic form thereof, are provided.
